PharmaCyte Biotech Inc (PMCB)

[TPX]

PharmaCyte Biotech Inc. >>> Insulin / Type 1 Diabetics / Cell-in-a-box >>>

Cells Producing Insulin By Themselves To Replace Injections

March 27 2015

Insulin injections might soon be a thing of the past; at least, for Type 1 diabetes patients. A team of Australian researchers have synthesised cells that produce the hormone insulin which could be the answer to that form of diabetes. The cells might soon be used in the world’s first artificial pancreas. The license was granted by the US biotechnology company PharmaCyte Biotech last October.



Type 1 diabetes is an autoimmune disease whereby the patient’s islet cells of the pancreas are attacked by his immune system such that the regulation of blood glucose becomes problematic.

The new cells that have been formed are called Melligen cells and they were derived from human liver cells; the liver and the pancreas are known to be forming from the same primordial cells, and, therefore, the liver cells were easily genetically modified to function as the insulin-producing cells, the islet cells.

Results showed that the GM Melligen cells released insulin as a response to the level of glucose found in their surroundings. The findings were so fruitful that the researchers concluded that they could help type 1 diabetes patients to decrease their dependency on daily injections; their blood sugar concentrations could be tuned naturally via these cells.

The Melligen cells will now have to be incorporated into the Cell-in-a-box® capsule. The latter which is about the same size as a pin head is a cellulose-based capsule that houses cells and later integrates them into the human body.

Another future step of the researchers will entail the transplantation of the artificial pancreases into animals. Thereafter, testing on humans will hopefully be possible.

http://news.islandcrisis.net/2015/03/cells-producing-insulin-by-themselves-to-replace-injections/

Type 1 Diabetics Will Soon Have Artificial Pancreases That Will Produce Insulin, Completely Eliminating The Need For Daily Injections

March 27, 2015



Insulin producing cells, created in a laboratory, will soon eliminate daily injections for type 1 diabetics.

Australian scientists have succeeded in creating cells that produce insulin on their own. These cells can potentially make daily insulin injections redundant. Scientists from the University of Technology, Sydney (UTS) managed to create these cells from regular liver cells, and they are already gearing up to incorporate them to a world-first bio-artificial pancreas after being licensed by U.S. biotechnology company PharmaCyte Biotech last October.

PharmaCyte Biotech has an innovative delivery mechanism, called the Cell-in-a-Box system, which is basically a tiny cellulose-based “capsule” that can house artificial cells and integrate them into a human body. This platform is quite revolutionary in the sense that it can be tweaked to develop treatments for any disease where cells aren’t releasing the molecules they’re supposed to. After acquiring the license to the insulin-producing cells, it’s clear that PharmaCyte Biotech has set their sights on Type 1 diabetes.

Type 1 diabetes is essentially an autoimmune disease that occurs when a person’s immune system attacks their pancreas’s islet cells and prevents them from properly regulating the body’s blood glucose levels, which is done by the timely release of insulin in controlled quantities.

Explaining why the new cell line, called as “Melligen” cells, is derived from healthy liver cells, instead of pancreatic cells, Ann Simpson from UTS: Science, who has been developing the cells over the past 20 years, offered the following explanation.

“When a fetus develops, the liver and the pancreas form from the same endodermal origin. This means that they should have the potential to do the same things as one another.”

Accordingly, healthy human liver cells have been genetically modified to take over the role of the pancreas’s insulin-producing islet cells. So far, lab trials have been very promising, with these tweaked cells being able to release insulin in direct response to the amount of glucose in their surroundings. In a person suffering from type 1 diabetes, this work has to be done by painful injections.

The team plans to transplant artificial pancreases into animals to test whether they can effectively integrate into the body and regulate insulin levels. After that, they can begin testing the technology in humans.

Diabetes is one of the most common diseases of the modern world, and the epidemic is growing alarmingly. Fortunately, scientists are busy devising innovative and non-invasive ways to treat diabetes and help people lead a normal live.

http://www.inquisitr.com/1960140/type-1-diabetics-will-soon-have-artificial-pancreases-that-will-produce-insulin-completely-eliminating-the-need-for-daily-injections/

Pharmacyte Biotech Inc (OTCMKTS:PMCB) Gaines Analysts Attention



March 27, 2015

Pharmacyte Biotech Inc (OTCMKTS:PMCB) is on a run after it gained appreciation from two small-cap research companies. The stock jumped up by nearly 29% to $0.147 during the yesterday trade, where an average volume of 1.81 million shares changed hands. Firstly, the company received coverage from TickerResearch, which said that the company’s Cell-in-a-Box technology has a great potential to a breakthrough in the treatment of pancreatic cancer.

Cell-in-a-box

The research firm said that Pharmacyte Biotech Inc (OTCMKTS:PMCB) holds exclusive rights to develop therapies to treat solid cancerous tumors through its Cell-in-a-box technology in combination with drug ifosfamide in low combinations. The firm added that Pharmacyte Biotech Inc (OTCMKTS:PMCB) already has earned Orphan Drug Status for its technology that puts it ahead in the race of developing treatment for advanced pancreatic cancer.

The company is expected to clinical trials to test the efficacy and effectiveness of its solution against industry standard treatment, Gemcitabine. If the company can report positive results from trial, then it will be its turning point. The research firm stated that Pharmacyte Biotech Inc (OTCMKTS:PMCB) could be the next biotech winner in the market.

More hidden potential

Similarly, another research firm, Goldman Small Cap Research too take a positive view on the stock. The firm’s analyst Rob Goldman said that the company is positioned attractively, where it has a caliber to develop a therapy for the treatment of multiple forms of diabetes and cancer. The research firm reiterated that the Orphan Drug status will boost the company’s development efforts and could make it as a chief player in the treatment of pancreatic cancer.

The firm suggested that the potential of the company has been overlooked, and there is a lot more value in the stock than estimated. The firm also highlighted the possibility that the company’s technology has the chances to cure a number of diseases including diabetes and other forms of cancer.

http://www.journaltranscript.com/2015/03/pharmacyte-biotech-inc-otcmktspmcb-gaines-analysts-attention/